The Clinical Study of Analgecine for the Treatment of Neuropathic Pain

NCT02633618 Phase 3 COMPLETED

A randomized, open-label , positive drug controlled (Neurotropin,Japan organs Pharmaceutical Co., Ltd. ), multi-center study to evaluate Analgecine's efficacy and safety for the treatment of neuropathic pain.

Details

Lead sponsor	VanWorld Pharmaceutical (Rugao) Company Limited
Phase	Phase 3
Status	COMPLETED
Enrolment	135
Start date	2005-08
Completion	2005-12

Conditions

• Neuropathic Pain

Interventions

• Analgecine
• Neurotropin

Primary outcomes

• Change of visual analog scale on pain — 2 weeks
  Pain was scored by VAS 10 points (visual analog scale). The degree of pain gradually increases from 0 to 10. The subtraction mark rate of VAS value before and after treatment and the grade decrease of associated symptoms will be regarded as the main curative effects indexes.